1. Home
  2. DRDB vs OLMA Comparison

DRDB vs OLMA Comparison

Compare DRDB & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DRDB
  • OLMA
  • Stock Information
  • Founded
  • DRDB 2024
  • OLMA 2006
  • Country
  • DRDB United States
  • OLMA United States
  • Employees
  • DRDB N/A
  • OLMA N/A
  • Industry
  • DRDB
  • OLMA Biotechnology: Pharmaceutical Preparations
  • Sector
  • DRDB
  • OLMA Health Care
  • Exchange
  • DRDB Nasdaq
  • OLMA Nasdaq
  • Market Cap
  • DRDB 315.3M
  • OLMA 378.9M
  • IPO Year
  • DRDB 2024
  • OLMA 2020
  • Fundamental
  • Price
  • DRDB $10.28
  • OLMA $5.46
  • Analyst Decision
  • DRDB
  • OLMA Strong Buy
  • Analyst Count
  • DRDB 0
  • OLMA 5
  • Target Price
  • DRDB N/A
  • OLMA $24.00
  • AVG Volume (30 Days)
  • DRDB 91.6K
  • OLMA 450.7K
  • Earning Date
  • DRDB 01-01-0001
  • OLMA 08-11-2025
  • Dividend Yield
  • DRDB N/A
  • OLMA N/A
  • EPS Growth
  • DRDB N/A
  • OLMA N/A
  • EPS
  • DRDB N/A
  • OLMA N/A
  • Revenue
  • DRDB N/A
  • OLMA N/A
  • Revenue This Year
  • DRDB N/A
  • OLMA N/A
  • Revenue Next Year
  • DRDB N/A
  • OLMA N/A
  • P/E Ratio
  • DRDB $587.54
  • OLMA N/A
  • Revenue Growth
  • DRDB N/A
  • OLMA N/A
  • 52 Week Low
  • DRDB $9.87
  • OLMA $2.86
  • 52 Week High
  • DRDB $10.43
  • OLMA $13.93
  • Technical
  • Relative Strength Index (RSI)
  • DRDB N/A
  • OLMA 54.42
  • Support Level
  • DRDB N/A
  • OLMA $5.54
  • Resistance Level
  • DRDB N/A
  • OLMA $5.85
  • Average True Range (ATR)
  • DRDB 0.00
  • OLMA 0.30
  • MACD
  • DRDB 0.00
  • OLMA -0.01
  • Stochastic Oscillator
  • DRDB 0.00
  • OLMA 51.79

About DRDB Roman DBDR Acquisition Corp. II Ordinary shares

Roman DBDR Acquisition Corp II is a blank check company.

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: